Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
Commercial Companies Coronavirus COVID-19

Coronavirus Update: After FDA Sneaks Out Guidance, Trump’s Vaccine Dream Is Over

Plus Europe Fast Tracks Pfizer/BioNTech Vaccine

  • News

Executive Summary

After threats to overrule the agency, the Trump administration has indicated that the stricter guidance will be allowed to stand.

You may also be interested in...



Pfizer’s First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off

Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.

EMA Starts ‘Rolling Review’ Of AstraZeneca’s COVID-19 Vaccine

The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.

Coronavirus Update: Moderna Still Confident Of November Readout

The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.

Table

View full table

Topics

Related Companies

Tags:
Commercial Companies Coronavirus COVID-19
UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By